Hasten Biopharmaceutical

CompanyChina

Hasten Biopharmaceutical develops one asset, approved (lerodalcibep in hypercholesterolemia). Mostly protein or enzyme acting on PCSK9; based in China.

1
Asset
Furthest stage
Approved
2
Trials
7
Signals

Pipeline

1
  • lerodalcibep

    Inhibits PCSK9, preserving LDL receptors and increasing clearance of LDL cholesterol from blood.

    Approved, Protein or enzyme, PCSK9, hypercholesterolemia, heterozygous familial hypercholesterolemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Signals13
  • Similar companies6

Intelligence